▴ Low-dose ethinylestradiol/levonorgestrel 20μg/ 100μg is a combined oral contraceptive that prevents pregnancy primarily by inhibiting ovulation.
▴ The Pearl index (pregnancies per 100 woman-years of use) with ethinylestradiol/levonorgestrel 20μg/ 100μg was 0.88 and the cumulative pregnancy rate was 1.9% at the end of a 3-year open-label trial (1708 women with 26 554 evaluable cycles). The contraceptive efficacy of ethinylestradiol/levonorgestrel 20μg/100μg was similar to that of other low-dose combined oral contraceptives containing ethinylestradiol 20 or 35μg in a 6-cycle trial (463 evaluable women).
▴ Ethinylestradiol/levonorgestrel 20μg/100μg is well tolerated; adverse events were those commonly associated with combined oral contraceptives. Headache and metrorrhagia (2% of women) were the most common adverse events leading to treatment discontinuation in the 3-year trial.
▴ Cycle control in open-label trials in women receiving up to 36 cycles of ethinylestradiol/levonorgestrel 20μg/100μg was generally good, with the incidence of intermenstrual bleeding being highest during the first few cycles of use and decreasing thereafter.
KeywordsOral Contraceptive Levonorgestrel Ethinylestradiol Combine Oral Contraceptive Contraceptive Efficacy
At the request of the journal, Wyeth Pharmaceuticals Inc. provided a non-binding review of this article.
- 2.Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982–2002. Hyattsville (MD): National Institutes of Health, National Center for Health Statistics, 2004. Advance Data From Vital and Health Statistics. Report no.: 350Google Scholar
- 3.Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001 Nov; 41(6): 875–86Google Scholar
- 4.Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®): North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 1999 Nov; 181: S39–44CrossRefGoogle Scholar
- 5.Wyeth Pharmaceuticals Inc. Alesse® 28 tablets (levonorgestrel and ethinyl estradiol tablets): US prescribing information 2004 Apr [online]. Available from URL: http://www.wyeth.com [Accessed 2005 Sep 7]
- 9.Reisman H, Martin D, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. Am J Obstet Gynecol 1999; 181: S45–52CrossRefGoogle Scholar
- 16.The European Agency for the Evaluation of Medicinal Products. EMEA Committee for Proprietary Medicinal Products public assessment report-combined oral contraceptives and venous thromboembolism 2001 Sep 28 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/regaffair/0220101en.pdf [Accessed 2005 Oct 4]
- 17.DelConte A, Loffer F, Grubb GS. Cycle control with oral contraceptives containing 20 μg of ethinyl estradiol: a multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 μg/20 μg) and norethindrone/ethinyl estradiol (1000 μg/20 μg). Contraception 1999; 59(3): 187–93PubMedCrossRefGoogle Scholar
- 18.Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 μg/20 μg versus triphasic norethindrone/ethinylestradiol 500-750-1000 μg/ 35 μg: a multicenter, randomized, open-label study. Eur J Contracept Reprod Health Care 1999 Jun; 4(2): 75-83PubMedCrossRefGoogle Scholar